ASCO preview: Merck ' s Keytruda, Novartis ' Kisqali face their moment of truth in early-stage cancers

Two cancers studies are slated to grab significant attention at the upcoming American Society of Clinical Oncology 2023 annual meeting, and each could lead to a major label expansion for the compan | Before the annual ASCO meeting, Fierce Pharma gathered expectations for two important early-stage…#fiercepharma #pennmedicine
Source: Reuters: Health - Category: Consumer Health News Source Type: news